# CheckMate 459 (NCT02576509)

> An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

No report yet. It can be ordered.

- Drugs tested: nivolumab
- Indication: first-line advanced hepatocellular carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02576509
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Hepatocellular Carcinoma
- Interventions: Nivolumab; Sorafenib
- Enrollment: 743
- Primary outcome: Overall Survival (OS)

## Questions raised in the commentary

_Automated from the 24 newest of 32 indexed sources (Nov 2018 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether biomarkers can identify patients likely to benefit from nivolumab
- Whether viral versus non-viral etiology modifies checkpoint inhibitor benefit
- Whether Wnt/β-catenin status can guide treatment selection

Also discussed: single-agent versus combination immunotherapy, withdrawal of nivolumab's HCC indication.

## Indexed commentary on CheckMate 459 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 20
- Podcasts: 7
- YouTube: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-459-nct02576509

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02576509", "email": "<work email>"}; the inbox owner confirms by the emailed link.